A clinical trial has started at the Evangelical Medical Centre in Bunia to test remdesivir and the antibody MBP134, with initial patients enrolled under enhanced security and 28-day survival follow-up.The World Health Organization, Congo's National Institute for Biomedical Research, Oxford University and the Institute of Tropical Medicine in Antwerp back the study, which aims for up to 1,000 participants and a second phase for healthcare workers and close contacts.Officials report inconsistent outbreak counts—national figures top 1,000 cases with 267 deaths while
WHO lists more than 1,400 cases and 438 deaths—and researchers say mistrust, violence and delays seeking care could limit enrollment.